Last updated 2026-06-18
- Went public, Jan 2012
- Raised $115M funding round, Feb 2020
- Raised $36M funding round led by Cosmo Pharmaceuticals, Oct 2019
Total raised
$307.1M
Last: 2026-06
Stage
Public
Founded
2009
Headcount
48
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
RedHill Biopharma is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on its promises, to build a company at the forefront of gastrointestinal and infectious diseases management.
Its two FDA-approved drugs are promoted in the U.S. by a dedicated and experienced sales team: Talicia and Aemcolo.
RedHill has also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.
Funding history · 14 rounds · $307.1M total
2026-06
$6.0M
2026-06
$19.4M
2025-10
2024-01
$8.0M
2023-12
Grant
$4.8M
2023-04
$6.0M
2022-05
$15.0M
2021-11
$10.0M
2020-02
$115.0M
2019-10
$36.0M
2014-01
2012-12
$6.5M
2010-11
Date unknown
$1.3M
Q&A
- What was RedHill Biopharma's net income for the first half of 2023?
- RedHill Biopharma reported a net income of $51 million for the first half of 2023, a significant improvement compared to a net loss of $32.2 million for the same period in 2022.
- What is the status of RedHill Biopharma's drug opaganib for neuroblastoma?
- In August 2024, the FDA granted orphan-drug designation to opaganib for the treatment of neuroblastoma, a type of childhood cancer. This designation provides a seven-year marketing exclusivity period upon approval and other potential benefits.
- What is the latest development regarding RedHill Biopharma's Talicia in the Middle East?
- In October 2025, RedHill Biopharma signed a licensing deal for its FDA-approved therapy, Talicia, to enter new Middle East markets. The agreement includes $500,000 in guaranteed payments, potential milestone payments of at least $1.3 million, and tiered royalties on net sales.
- What is the current status of RedHill Biopharma's compliance with Nasdaq's minimum stockholders' equity requirement?
- As of November 26, 2025, RedHill Biopharma successfully regained compliance with Nasdaq's stockholders' equity requirement.
- What is the status of RedHill Biopharma's RHB-102 for oncology support in the UK?
- In February 2023, RedHill Biopharma announced plans to submit a Marketing Authorisation Application (MAA) to the UK MHRA for RHB-102 (Bekinda) for oncology support, specifically for chemotherapy and radiotherapy-induced nausea and vomiting.
- What is the latest development regarding RedHill Biopharma's opaganib for Acute Radiation Syndrome (ARS)?
- In February 2023, RedHill Biopharma received positive feedback from the FDA regarding the development of opaganib for Acute Radiation Syndrome (ARS), including guidance on its developmental pathway to potential approval under the Animal Rule.
- What was the outcome of RedHill Biopharma's legal case against Kukbo Co. Ltd. in the New York Supreme Court?
- In November 2025, RedHill Biopharma announced a legal victory in the New York Supreme Court against Kukbo Co. Ltd., resulting in a financial award of over $10.5 million, including a main judgment of approximately $8.6 million and legal fees.
- What is the status of RedHill Biopharma's RHB-107 in a U.S. government-supported COVID-19 study?
- In April 2024, RedHill Biopharma announced the enrollment of the first patient in a global, 300-patient, Phase 2 adaptive platform trial for RHB-107 (upamostat) for early COVID-19 outpatient treatment, funded through non-dilutive external sources including the U.S. Department of Defense.
Team · 1
Founder · Co-Founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
inflammatory-diseasescrohn-s-diseasebiopharmaceuticaloral-drugsmedical-productsgastroenterologypharmaceuticalsoncologyhealthcare-providersorphan-drugpatientsinfectious-disease
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | redhillbio.com/home/default.aspx |
|---|---|
| linkedin.com/company/2259672 |
Identifiers & details
| Founded | 2009-8 |
|---|---|
| Employees (exact) | 48 |
| Offices | Raleigh |
| Market cap | $5.2M |
| Status reason | Public on NASDAQ on Jan, 2012; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2022-12 | $8.0M | |||
| 2021-11 | $15.5M | |||
| 2021-03 | $35.0M | |||
| 2020-02 | ||||
| 2018-12 | $20.0M | |||
| 2016-12 | $38.0M | |||
| 2015-07 | $40.0M | |||
| 2015-02 | $12.0M | |||
| 2012-12 | ||||
| 2012-01 |